top of page

Aug 6

The CEO of UK based Levicept shares background on the company's neurotrophin-3 inhibiting fusion protein, which they say succeeded today in pain management in an osteoarthritis phase 2 study

Eliot Forster describes the scientific rational of inhibiting NT-3 while avoiding nerve growth factor and the side effects that come with it.

Recent Posts

ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets

ASH 2024: Arcellx CEO Rami Elghandour discusses a data update of the iMMagine-1 Study for the company's BCMA CAR-T

ASH 2024: Beam's CEO John Evans on the company's based editing sickle cell data, and preclinical data on a next generation product meant to broaden the potential patient population

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh

bottom of page